NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on natural killer cell-based immunotherapies, with a primary research emphasis on neurodegenerative diseases including Alzheimer's disease. The company completed its SPAC business combination with Graf Acquisition Corp. IV in 2023, with the transaction sponsored by Graf Holdings; it began trading on Nasdaq under the ticker NKGN following the close of that merger. NKGen operates in the cell therapy segment of the broader biotechnology sector and continues to advance its NK-cell platform through clinical development. The company filed the referenced 8-K with the SEC on September 2, 2026. For full filing history, event details, and institutional data on NKGN and hundreds of other de-SPAC companies, sign up for complete access at SpacDesk.